Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

STRategies for Optimised bioprinting of Next Generation tissues for URethral regeneration and translation (STRONG-UR)

Project description

Advanced bioprinting for urethral tissue regeneration

Urethral strictures affect 0.6 % of males, leading to significant health and economic challenges. Repair methods are essential, and while bioprinting shows promise, a gap remains between research and clinical application. In this context, the EU-funded STRONG-UR project will develop bioprinted tubular tissue constructs for urethral tissue engineering. It will create modular, scalable bioprinter components and smart bioinks that can be personalised for individual constructs, enabling noninvasive monitoring and real-time treatment assessments. Two main strategies are proposed: a single-stage in situ bioprinting method for faster clinical translation and a multistage approach using GMP-manufactured components to enhance vascularisation and tissue healing. It also introduces an in vitro urethral model for more ethical and reliable preclinical testing.

Objective

STRONG-UR aims to revolutionise surgical tissue reconstruction by producing next-generation bioprinted tubular tissue constructs, focusing on urethral tissue engineering. Urethral strictures affect approximately 0.6% of the male population, leading to persistent physical and psychological impairment in patients and imposing a significant economic burden on healthcare systems. The lack of effective techniques to heal and repair diseased urethras emphasises the urgent need to invest in innovative regenerative approaches. In this direction, bioprinting offers promising prospects through the production of customised tissue constructs with controlled cell composition and architecture. However, there is still a significant gap between laboratory studies and clinical application, which is why there is currently no reliable technology available for clinical use. STRONG-UR includes the development of modular, scalable bioprinter components and bioinks to bridge the current gap. The bioinks comprise smart hydrogels customisable to personalised urethral constructs, supporting desired cellular functions and enabling non-invasive monitoring for real-time treatment assessment. Two different approaches are proposed: a single stage in situ bioprinting approach for accelerated clinical translation and a multistage approach using GMP-manufactured components to induce vascularisation and promote tissue healing. In addition, a novel bioprinted in vitro urethral model is proposed as a human-based testing platform for more ethical and reliable preclinical assessments. The project is in line with EU health policy, addressing unmet clinical needs and supports a Europe fit for the digital age. With a 12-partner consortium composed of scientists, clinicians, and companies contributing to the whole value chain, supported by a state-of-the-art infrastructure and a proven track record of successful projects in this field, STRONG-UR represents the best team to deliver this ground-breaking work.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-TOOL-11

See all projects funded under this call

Coordinator

AALBORG UNIVERSITET
Net EU contribution
€ 1 522 693,75
Address
FREDRIK BAJERS VEJ 7K
9220 Aalborg
Denmark
Region
Danmark Nordjylland Nordjylland
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 522 693,75

Participants (11)